Related Experiment Videos
Fostering chemopreventive agent development: how to proceed?
1Biomarkers and Prevention Research Branch, National Cancer Institute, National Institutes of Health, Rockville, MD 20850-3300, USA.
Journal of Cellular Biochemistry. Supplement
|January 1, 1995
Summary
Developing new cancer prevention drugs faces challenges like high costs and uncertain outcomes, hindering progress. Overcoming these barriers, inspired by vaccine development, is crucial for advancing cancer control strategies.
Area of Science:
- Oncology
- Pharmacology
- Cancer Prevention Research
Background:
- Early cancer detection via molecular methods enables targeted therapies.
- Cancer prevention research is vital for reducing mortality but requires significant resources.
- Pharmaceutical industry historically supported cancer treatment development more than prevention.
Purpose of the Study:
- Identify barriers hindering the development of chemoprevention agents.
- Explore potential solutions and parallels with past drug development challenges.
- Accelerate progress in cancer prevention strategies.
Main Methods:
- Analysis of preliminary discussions with pharmaceutical and biotech industry representatives.
- Review of factors impacting chemoprevention product development, including costs and liability.
- Examination of historical challenges in childhood vaccine development for applicable insights.
Main Results:
- Significant barriers exist for chemoprevention drug development, including clinical trial costs and uncertain liability.
- Promising chemoprevention agents are being overlooked due to development uncertainties.
- Childhood vaccine development faced similar issues, offering potential solutions.
Conclusions:
- Addressing barriers in chemoprevention development is critical for advancing cancer control.
- Industry and federal support models need re-evaluation for prevention agents.
- Lessons from vaccine development can inform and improve cancer prevention strategies.